• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

15 August 2019

Baqsimi nasal powder ( glucagon), first treatment for severe hypoglycemia that can be administered without an injection


0 Comments4 Minutes

9 August 2019

Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation


0 Comments4 Minutes

17 July 2019

Victoza, liraglutide, new treatment for children with type 2 diabetes


0 Comments4 Minutes

16 July 2019

Dupixent (dupilumab), first treatment for chronic rhinosinusitis with nasal polyps


0 Comments3 Minutes

10 July 2019

FDA approves Soliris (eculizumab), first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system


0 Comments5 Minutes

10 July 2019

FDA approves Xpovio (selinexor), new treatment for refractory multiple myeloma


0 Comments5 Minutes

31 May 2019

Piqray (alpelisib), first PI3K inhibitor for breast cancer


0 Comments6 Minutes

26 May 2019

Zolgensma (onasemnogene abeparvovec-xioi), innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality


0 Comments7 Minutes

18 May 2019

FDA approves Fragmin (dalteparin sodium) first anticoagulant for pediatric patients to treat potentially life-threatening blood clots


0 Comments4 Minutes

7 May 2019

Dengvaxia, the first vaccine approved by FDA for the prevention of dengue disease caused by all dengue virus serotypes


0 Comments6 Minutes

  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13